These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33323531)

  • 21. Improving Pneumococcal Vaccination in Pediatric Rheumatology Patients.
    Harris JG; Maletta KI; Ren B; Olson JC
    Pediatrics; 2015 Sep; 136(3):e681-6. PubMed ID: 26304825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta-analysis.
    Britt AF; Poupore NS; Nguyen SA; White DR
    Otolaryngol Head Neck Surg; 2023 Mar; 168(3):291-299. PubMed ID: 35852861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
    Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis.
    Baker DW; Brown T; Lee JY; Ozanich A; Liss DT; Sandler DS; Ruderman EM
    J Rheumatol; 2016 Jun; 43(6):1030-7. PubMed ID: 27084914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant.
    Malone K; Clark S; Palmer JA; Lopez S; Pradhan M; Furth S; Kim J; Fisher B; Laskin B
    Pediatr Transplant; 2016 Sep; 20(6):783-9. PubMed ID: 27334506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
    Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
    Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics.
    Harris JG; Harris LA; Olarte L; Elson EC; Moran R; Blowey DL; El Feghaly RE
    Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35233616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination Rates in Patients With Medical Indications for the Pneumococcal Polysaccharide Vaccine in a Family Medicine Clinic.
    Trovato A; Gunning K; Pippitt K
    J Pharm Pract; 2019 Apr; 32(2):154-157. PubMed ID: 29226755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving influenza and pneumococcal vaccination uptake among incident peritoneal dialysis patients: a quality improvement initiative.
    Tan HZ; Phang CC; Wu SY; Sim MH; Law MM; Foo MWY; Htay H
    Int Urol Nephrol; 2021 Oct; 53(10):2167-2175. PubMed ID: 33675479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality.
    Desai SP; Turchin A; Szent-Gyorgyi LE; Weinblatt M; Coblyn J; Solomon DH; Kachalia A
    Rheumatology (Oxford); 2011 Feb; 50(2):366-72. PubMed ID: 20974614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the Combination Pneumococcal Vaccination Rate in Systemic Lupus Erythematosus Patients at an Adult Rheumatology Practice.
    Garg S; Tsagaris K; Cozmuta R; Lipson A
    J Rheumatol; 2018 Dec; 45(12):1656-1662. PubMed ID: 30173154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.